The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Learn more about immunotherapy and the role it plays in treating renal cell carcinoma.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 3/5/25.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online nursing continuing professional development evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.
Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):
Planning Committee Disclosures: Diane Newman, DNP, CRNP, FAAN, BCB-PMD - Advisory Board for EBT Medical, Coloplast, and ConvaTec; conducts research for Hollister; editor for Digital Science Press
There are no other Planning Committee disclosures to declare.
Speaker Disclosures: There are no speaker disclosures to declare.
Commercial Support: No commercial support declared.
Accreditation Statement: The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of NCPD does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the requirements for re-licensure in the states in which they hold a license.
Learning Outcome: After completing this learning activity, the participant will be able to review the current frontline immune checkpoint treatments of metastatic RCC disease, discuss the results of triplet therapy, and review the impact of immune peri-operative therapy trials on the current frontline treatments.